Acquisition of Proteolix (Details) (Proteolix, USD $) In Millions, unless otherwise specified	3 Months Ended
Mar. 31, 2013 item	Nov. 16, 2009
Proteolix
Acquisition of Proteolix disclosures
Cash consideration paid for acquisition		$ 276.0
Number of potential future earn out payments	3
Potential contingent consideration payment	$ 365

Amount of cash paid to acquire the entity.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 68

-Subparagraph f(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Name:	us-gaap_BusinessAcquisitionCostOfAcquiredEntityCashPaid
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant